Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy

Documenti analoghi

• Comment on: ‘Preferences between three options for androgen deprivation therapy…’
  di: Richard Wassersug, et al.
  Pubblicazione: (2025)
• Preferences between three options for androgen deprivation therapy: a focus group study
  di: Hannah L. Rush, et al.
  Pubblicazione: (2025)
• Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer
  di: Pär Stattin, et al.
  Pubblicazione: (2024)
• Urologist underutilisation of androgen receptor pathway inhibitors for metastatic hormone‐sensitive prostate cancer
  di: Daniel Crisafi, et al.
  Pubblicazione: (2024)
• Post‐cycle therapy after short‐term anabolic‐androgenic steroid use: comparative outcomes in recreational bodybuilders
  di: Muhammed Arif İbis, et al.
  Pubblicazione: (2025)